网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
肽P11通过上调miR-126表达抑制分化型甲状腺癌细胞增殖和侵袭
作者:边芳1  李宁2  李奇3 
单位:1. 陕西省友谊医院 内分泌科, 陕西 西安 710068;
2. 西安交通大学第一附属医院 肿瘤内科, 陕西 西安 710061;
3. 西安交通大学第一附属医院 神经外科, 陕西 西安 710061
关键词:分化型甲状腺癌 肽P11 miRNA-126 脂蛋白受体相关蛋白6 Wnt/β-catenin信号通路 
分类号:R736.1
出版年·卷·期(页码):2021·49·第八期(833-840)
摘要:

目的:揭示肽P11对人分化型甲状腺癌细胞生长和转移的影响,以及肽P11与miRNA-126表达之间的关联。方法:采用qRT-PCR分别检测30份乳头状甲状腺癌和滤泡性甲状腺癌组织及配对癌旁组织中miR-126的表达。分别应用miR-126模拟物转染TPC-1和FTC-133细胞系。应用500 μmol·L-1的肽P11培养两种甲状腺癌细胞24 h。采用MTT法测定细胞活力,膜联蛋白V (Annexin V)-FITC/碘化丙啶(PI)测定法检测细胞凋亡,伤口愈合实验检测细胞迁移,Transwell小室侵袭实验检测细胞侵袭,Western blot检测脂蛋白受体相关蛋白6(LRP6)及Wnt/β-catenin信号通路下游基因MMP-7、c-Myc和cyclin D1的表达。结果:miR-126在分化型甲状腺癌组织和细胞系中表达下调(P<0.05),并且miR-126的异常表达与TNM分期和淋巴结转移相关(P<0.05)。肽P11处理显著上调了分化型甲状腺癌细胞中miR-126的表达(P<0.05)。肽P11处理和miR-126的过表达均抑制了分化型甲状腺癌细胞的增殖、迁移和侵袭,并诱导细胞凋亡(P<0.05)。肽P11处理和miR-126的过表达下调了细胞中LRP6、MMP-7、c-Myc和cyclin D1的表达(P<0.05)。结论:肽P11可通过上调分化型甲状腺癌细胞中miR-126的表达来发挥抗癌作用。miR-126可能是乳头状甲状腺癌治疗的潜在靶标,而肽P11可通过靶向miR-126来发挥抗癌作用。

Objective: To discuss the effect of peptide P11 on the growth and metastasis of human differentiated thyroid cancer cells, and the relationship between peptide P11 and miRNA-126 expression.Methods: qRT-PCR was used to detect the expression of miR-126 in 30 papillary thyroid carcinoma and follicular thyroid carcinoma tissues and matched paracancerous tissues. The TCR-1 and FTC-133 cell lines were transfected with miR-126 mimics, respectively. Two kinds of thyroid cancer cells were cultured for 24 h with 500 μmol·L-1 peptide P11. Cell viability was determined by MTT assay, apoptosis was detected by Annexin V-FITC/propidium iodide(PI) assay, cell migration was detected by wound healing assay, cell invasion was detected by Transwell chamber invasion assay, and expression of lipoprotein receptor-associated protein 6(LRP6) and downstream genes of Wnt/β-catenin signaling pathways MMP-7, c-Myc and cyclin D1 was detected by Western blot.Results: The expression of miR-126 was down-regulated in differentiated thyroid carcinoma tissues and cell lines(P<0.05), and the abnormal expression of miR-126 was associated with TNM staging and lymph node metastasis(P<0.05). Peptide P11 treatment significantly up regulated the expression of miR-126 in differentiated thyroid cancer cells(P<0.05). Peptide P11 treatment and overexpression of miR-126 inhibited proliferation, migration and invasion and induced apoptosis of differentiated thyroid cancer cells(P<0.05). Peptide P11 treatment and overexpression of miR-126 down regulated the expression of LRP6, MMP-7, c-Myc and cyclin D1 in cells(P<0.05). Conclusion: Peptide P11 can exert anti-cancer effect by up-regulating the expression of miR-126 in differentiated thyroid cancer cells. miR-126 may be a potential target for PTC treatment, while peptide P11 can exert anticancer effects by targeting miR-126.

参考文献:

[1] 上官琳珏, 赵春雷.分化型甲状腺癌及其失分化机制的研究进展[J]. 癌症进展, 2019, 17(16):1861-1865.
[2] YUAN Q, LIU Y, FAN Y, et al. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637[J]. International Journal of Biochemistry & Cell Biology, 2018, 98:1-9.
[3] DONNEM T, REYNOLDS A R, KUCZYNSKI E A, et al. Non-angiogenic tumours and their influence on cancer biology[J]. Nature Reviews Cancer, 2018, 18(5):323-336.
[4] 陈孝霞, 辜臻晟.细胞因子在角膜新生血管和淋巴管生成中效应研究[J]. 中国实用眼科杂志, 2017, 35(6):558-562.
[5] WU D, GAO Y, QI Y, et al. Peptide-based cancer therapy:opportunity and challenge[J]. Cancer Letters, 2014, 351(1):13-22.
[6] CHANG Y W, SU C M, SU Y H, et al. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects[J]. Oncotarget, 2014, 5(11):3823-3835.
[7] WU X, HUANG H, WANG C, et al. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation[J]. Oncotarget, 2013, 4(10):1819-1828.
[8] WU D, TIAN W, LI J, et al. Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway[J]. Molecular Biology Reports, 2019, 46(3):2665-2678.
[9] 秦宝山, 郭云霞, 韩莉.微小RNA-215-5p靶向eIF2a负向调控结肠癌细胞增殖[J]. 东南大学学报(医学版), 2020, 39(6):780-787.
[10] ZHAO C, LI Y, ZHANG M, et al. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2[J]. Human Cell, 2015, 28(2):91-99.
[11] KIM M K, JUNG S B, KIM J S, et al. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer[J]. Virchows Archiv, 2014, 465(4):463-471.
[12] KITANO M, RAHBARI R, PATTERSON E E, et al. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs[J]. Annals of Surgical Oncology, 2011, 18(12):3443-3452.
[13] AMR K S, ABDELMAWGOUD H, ALI Z Y, et al. Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease[J]. British Journal of Biomedical Science, 2018, 75(2):82-87.
[14] DU C, LV Z, CAO L, et al. miR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2[J]. Journal of Translational Medicine, 2014, 12(1):259-269.
[15] PERÖBNER I, KAROW M, JOCHUM M, et al. LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells[J]. The International Journal of Biochemistry & Cell Biology, 2012, 44(11):1970-1982.
[16] 范文强, 姬宇宙, 刘先本.癌蛋白LRP6调节FGF8信号对肺癌细胞增殖的影响研究[J]. 癌症进展, 2018, 16(5):54-57.
[17] 张毅, 钟自彪, 叶启发, 等.微小RNA-202可通过转录后下调低密度脂蛋白受体相关蛋白6的表达抑制人肝癌细胞增殖[J]. 中华实验外科杂志, 2015, 32(9):2154-2156.
[18] MA C, LUO C, YIN H, et al. Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion[J]. Gastric Cancer, 2018, 21(4):617-631.
[19] JOINER D M, KE J, ZHONG Z, et al. LRP5 and LRP6 in development and disease[J]. Trends in Endocrinology and Metabolism, 2012, 24(1):31-39.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 510039 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541